← Back to Screener
Natera, Inc. Common Stock (NTRA)
Price$207.74
Favorite Metrics
Price vs S&P 500 (26W)12.38%
Price vs S&P 500 (4W)-4.32%
Market Capitalization$29.44B
All Metrics
P/CF (Annual)136.75x
Book Value / Share (Quarterly)$12.26
P/TBV (Annual)23.67x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)41.14%
Cash Flow / Share (Quarterly)$0.54
Price vs S&P 500 (YTD)-13.25%
Gross Margin (TTM)64.75%
Net Profit Margin (TTM)-9.03%
EPS (TTM)$-1.53
10-Day Avg Trading Volume1.48M
EPS Excl Extra (TTM)$-1.53
Revenue Growth (5Y)42.61%
EPS (Annual)$-1.52
ROI (Annual)-11.61%
Gross Margin (Annual)64.75%
Net Profit Margin (5Y Avg)-40.52%
Cash / Share (Quarterly)$7.70
Revenue Growth QoQ (YoY)39.79%
ROA (Last FY)-8.68%
Revenue Growth TTM (YoY)35.90%
EBITD / Share (TTM)$-2.04
ROE (5Y Avg)-46.95%
Operating Margin (TTM)-13.44%
Cash Flow / Share (Annual)$0.54
P/B Ratio17.19x
P/B Ratio (Quarterly)18.50x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)12.34x
Net Interest Coverage (TTM)-57.80x
ROA (TTM)-10.80%
EPS Incl Extra (Annual)$-1.52
Current Ratio (Annual)3.39x
Quick Ratio (Quarterly)3.11x
3-Month Avg Trading Volume1.21M
52-Week Price Return40.29%
EV / Free Cash Flow (Annual)373.75x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$9.58
P/S Ratio (Annual)12.77x
Asset Turnover (Annual)0.96x
52-Week High$256.36
Operating Margin (5Y Avg)-41.71%
EPS Excl Extra (Annual)$-1.52
CapEx CAGR (5Y)48.00%
Tangible BV CAGR (5Y)94.40%
26-Week Price Return19.27%
Quick Ratio (Annual)3.11x
13-Week Price Return-13.56%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)3.39x
Enterprise Value$28,447.431
Revenue / Share Growth (5Y)28.43%
Asset Turnover (TTM)1.20x
Book Value / Share Growth (5Y)16.79%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)14.36x
Pretax Margin (Annual)-11.63%
Cash / Share (Annual)$7.70
3-Month Return Std Dev50.40%
Gross Margin (5Y Avg)52.81%
Net Income / Employee (TTM)$-0
ROE (Last FY)-12.16%
Net Interest Coverage (Annual)-39.23x
EPS Basic Excl Extra (Annual)$-1.52
P/FCF (TTM)386.84x
Receivables Turnover (TTM)7.55x
EV / Free Cash Flow (TTM)373.75x
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-1.53
Receivables Turnover (Annual)7.55x
ROI (TTM)-14.43%
P/S Ratio (TTM)12.77x
Pretax Margin (5Y Avg)-40.99%
Revenue / Share (Annual)$16.87
Tangible BV / Share (Annual)$9.58
Price vs S&P 500 (52W)5.66%
Year-to-Date Return-9.32%
5-Day Price Return-3.21%
EPS Normalized (Annual)$-1.52
ROA (5Y Avg)-25.55%
Net Profit Margin (Annual)-9.03%
Month-to-Date Return3.88%
Cash Flow / Share (TTM)$-4.30
EBITD / Share (Annual)$-2.25
Operating Margin (Annual)-13.44%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)136.75x
ROI (5Y Avg)-32.86%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.53
P/TBV (Quarterly)23.67x
P/B Ratio (Annual)18.50x
Inventory Turnover (TTM)14.36x
Pretax Margin (TTM)-11.63%
Book Value / Share (Annual)$12.26
Price vs S&P 500 (13W)-15.94%
Beta1.62x
P/FCF (Annual)386.84x
Revenue / Share (TTM)$16.67
ROE (TTM)-15.28%
52-Week Low$131.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.25
4.25
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $207.74 |
LHLabcorp Holdings Inc. | 25.31x | 7.25% | 9.92% | 10.28% | $269.19 |
DGXQuest Diagnostics Inc. | 21.75x | 11.78% | 14.10% | 13.88% | $196.31 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $91.07 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $57.85 |
VCYTVeracyte, Inc. | 39.66x | 16.01% | 11.17% | 5.33% | $33.45 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $51.20 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $21.29 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.44 |
CSTLCastle Biosciences, Inc. Common Stock | 47.31x | 3.66% | -12.44% | -5.27% | $25.16 |
About
Natera provides molecular diagnostic tests across reproductive health, oncology, and transplantation. Its main products include Panorama for non-invasive prenatal screening, Horizon for genetic carrier assessment, Signatera for circulating tumor DNA detection in cancer monitoring, and Prospera for organ transplant rejection assessment. The company leverages proprietary molecular and bioinformatics technology across these applications.